. Mean neutralising capacity of pooled ZIKV patients (shown in Figure 1e -f) and mean anti-ZIKV IgG levels of ZIKV patients were calculated for all time points (from acute to full recovery) and correlation was carried out. (b-d) Plasma samples from ZIKV (n=30-44) and serum samples from DENV (n=20) patients at late convalescent time point were tested for anti-ZIKV or anti-DENV IgG respectively at 1:2000 dilution, using purified ZIKV or DENV virions in a virion-based ELISA. In addition, plasma/serum samples were tested at 1:2000 dilution in duplicates for peptide-specific IgG using ZIKV and DENV peptides in a peptide-based ELISA. Patients' response to ZIKV and DENV peptide-pairs were compared and peptide binding capacity was calculated. Correlation of (b) both ZIKV and DENV patients' antibody response to common flavivirus peptides, (c) ZIKV patients' antibody response to ZIKV-specific peptides, and (d) DENV patients' antibody response to DENV-specific peptides. Correlation analysis was carried out using Spearman's rank correlation. Spearman's rho (!) and P-value (P) are presented. Based on Supplementary Table 3, the percentage of positive peptides were calculated and "outcome" of patients were assigned. † If sample is positive for 3 or more (out of 4) common flavivirus peptides, i.e. ≥75% positive, the patient is considered positive (indicated as "y" in the outcome) for flavivirus infection. If sample is ≤75% positive, the patient is considered negative (indicated as "n" in the outcome). ‡ If sample is positive for 2 or more (out of 3) ZIKV-specific peptides, i.e. ≥66.7% positive, the patient is considered positive (indicated as "y" in the outcome) for ZIKV infection. If sample is ≤66.7% positive, the patient is considered negative (indicated as "n" in the outcome). § If sample is positive for the DENV-specific peptide, i.e. ≥100% positive, the patient is considered positive (indicated as "y" in the outcome) for DENV infection, whereas negative for the DENV-specific peptide is indicated as "n" in the outcome. ¶ Based on the respective outcomes of the epitope categories, the following combinations produce the final ZIKV and DENV "diagnosis" of patients.
Common flavivirus ZIKV-specific DENV-specific Final "diagnosis" y y n ZIKV positive ("z") y n y DENV positive ("d") y n n ZIKV and DENV negative ("n") n y n n n y n n n
